Acute Respiratory Distress Syndrome (ARDS) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape

 Breaking News
  • No posts were found

Acute Respiratory Distress Syndrome (ARDS) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape

Acute Respiratory Distress Syndrome (ARDS) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Acute Respiratory Distress Syndrome therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The Acute Respiratory Distress Syndrome (ARDS) therapeutics market is anticipated to evolve immensely in the coming years, owing to the expected approval of emerging therapies and the increasing patient population of Acute Respiratory Distress Syndrome.  The pipeline for ARDS is dynamic, consisting of potential therapies such as EB05 (Edesa Biotech/Light Chain Biosciences), DB-001 (Direct Biologics), BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys/Healios), Alteplase (Boehringer Ingelheim/Genentech), and Lucinactant (Windtree Therapeutics) which are expected to launch in the near future. 

Acute Respiratory Distress Syndrome (ARDS) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acute Respiratory Distress Syndrome Market. 

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis

Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Acute Respiratory Distress Syndrome and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acute Respiratory Distress Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

  • Glucocorticoid receptor agonists

  • Nicotinamide phosphoribosyltransferase inhibitors

  • Cell replacement

  • TIE-2 receptor agonist

  • Myristoylated alanine-rich C kinase substrate inhibitors

  • Angiogenesis inhibitors

  • Angiogenesis inhibitors

Learn How the Ongoing Clinical & Commercial Activities will Affect the Acute Respiratory Distress Syndrome Therapeutic Segment @

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight

Acute Respiratory Distress Syndrome (ARDS) Therapeutics Landscape

  • Abbreos

  • Aerpio Pharmaceuticals

  • Apeiron Biologics

  • Athersys

  • Aviceda Therapeutics

  • AVM Biotechnology

  • Bayer

  • BioMarck Pharmaceuticals

  • Cartesian Therapeutics

  • CohBar

  • Cynata Therapeutics

  • Exvastat

  • Faron Pharmaceuticals

  • GEn1E Lifesciences

  • ImStem Biotechnology

  • Longeveron

  • Orbsen Therapeutics

  • Roivant Sciences

  • Sage Therapeutics

  • ZyVersa Therapeutics

And Many Others

Acute Respiratory Distress Syndrome (ARDS) Emerging and Marketed Drugs Covered in the Report Include:

  • Alteplase: Boehringer Ingelheim/ Genentech

  • AVTX-002 (CERC-002): Avalo Therapeutics

  • BDB-001: Staidson (Beijing) Biopharmaceuticals

  • BIO-11006: BioMarck Pharmaceuticals

  • EB05 (NI 0101): Edesa Biotech/Light Chain Biosciences

  • ExoFlo (DB-001): Direct Biologics

  • HCR040: Histocell, S.L.

  • HLCM051(MultiStem): Healios

  • ILT101: ILTOO Pharma

  • Lucinactant (sinapultide): Windtree Therapeutics

  • Metablok (LSALT peptide): Arch Biopartners

  • MN-166 (ibudilast): MediciNova

  • MultiStem (HLCM051): Athersys/ Healios

  • MultiStem: Athersys

  • PLX-PAD: Pluristem Therapeutics

  • Remestemcel-L: Mesoblast Limited

  • Sabizabulin (Veru-111): Veru

  • Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH

  • Zavegepant (BHV-3500): Biohaven Pharmaceutical

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Acute Respiratory Distress Syndrome Current Treatment Patterns

4. Acute Respiratory Distress Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Acute Respiratory Distress Syndrome Late Stage Products (Phase-III)

7. Acute Respiratory Distress Syndrome Mid-Stage Products (Phase-II)

8. Acute Respiratory Distress Syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Respiratory Distress Syndrome Discontinued Products

13. Acute Respiratory Distress Syndrome Product Profiles

14. Key Companies in the Acute Respiratory Distress Syndrome Market

15. Key Products in the Acute Respiratory Distress Syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Acute Respiratory Distress Syndrome Unmet Needs

18. Acute Respiratory Distress Syndrome Future Perspectives

19. Acute Respiratory Distress Syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight

 

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories